Pharvaris N.V. (PHVS)
NASDAQ: PHVS · Real-Time Price · USD
25.59
+1.57 (6.54%)
At close: Dec 19, 2025, 4:00 PM EST
26.16
+0.57 (2.23%)
After-hours: Dec 19, 2025, 7:30 PM EST
Pharvaris Employees
Pharvaris had 108 employees as of December 31, 2024. The number of employees increased by 26 or 31.71% compared to the previous year.
Employees
108
Change (1Y)
26
Growth (1Y)
31.71%
Revenue / Employee
n/a
Profits / Employee
-$1,778,624
Market Cap
1.66B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 108 | 26 | 31.71% |
| Dec 31, 2023 | 82 | 17 | 26.15% |
| Dec 31, 2022 | 65 | 31 | 91.18% |
| Dec 31, 2021 | 34 | 20 | 142.86% |
| Dec 31, 2020 | 14 | 11 | 366.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PHVS News
- 16 days ago - Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript - Seeking Alpha
- 16 days ago - Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows - Benzinga
- 17 days ago - Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks - GlobeNewsWire
- 27 days ago - Pharvaris: Biotech With De-Risked Phase 3 Readout Coming, Initiating With A Buy Rating - Seeking Alpha
- 5 weeks ago - Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting - GlobeNewsWire
- 2 months ago - Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting - GlobeNewsWire
- 3 months ago - Pharvaris N.V. (PHVS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha